The PORTEC-3 trial continues to shape our understanding of adjuvant therapy in high-risk endometrial cancer. With updated 10-year follow-up data, it provides valuable insights into survival outcomes and the role of molecular classification in guiding treatment.

🔑 Key Highlights

Chemoradiotherapy vs Radiotherapy Alone
Long-term benefit in overall survival (OS) and recurrence-free survival (RFS) persists with combined modality treatment.

p53-abnormal (p53-abn) tumors
Patients derive a substantial survival advantage with chemoradiotherapy.

POLE-mutated cancers
Show an excellent prognosis regardless of treatment, supporting treatment de-escalation in this subgroup.

MMR-deficient (MMRd) & NSMP groups
Outcomes highlight the need for immunotherapy approaches and further risk stratification in these subsets.

 

🎥 Watch my detailed discussion on this trial and its clinical implications on my Journal Club Oncology channel: 👉 PORTEC-3 Trial Discussion – Dr. Pavan Kumar